|
|
 |
|
Biokeys Pharmaceuticals' viral entry inhibitor therapeutically targets diverse HIV-I strains Yahoo! Finance Biokeys Pharmaceuticals Inc. (OTCBB:BKYS) announced today that its HIV viral entry inhibitor, BlockAide/CR(TM) (R15K), which is being readied for human trials, appears to be interfering with an HIV infection step common to the entry of diverse HIV-1 strains.
—Posted: March 19, 2003
More news headlines: This week | Last week | Search archive
|
|
|
